Sao Paulo, June 14, 2023 - Eurofarma operates in 22 countries and has been recognized throughout time as one of the companies most committed to sustainability. This year, it has once again won the “Melhores do ESG Award” (“Best ESG Compliant Companies Award”), in the Pharmaceutics and Beauty category, thus becoming a six-time winner and remaining as the only company in the sector to hold such a record. Exame Magazine, a publication deemed to be one of the main economic and business magazines in Brazil, has been granting this award since 2000.

Altogether, more than 40 companies were awarded on Tuesday night, June 13th, during a ceremony held at Casa Charlô, in Sao Paulo. Maurizio Billi, Eurofarma’s CEO, received the trophy together with some of the company’s businesswomen. “Our history has always been built on solid foundations, a lot of hard work, and a long-term vision. We generate and share wealth, we have adopted the best governance practices, and we strive for eco-efficiency. Being granted one more recognition award makes all of us feel really proud of what we do”, commented the company’s CEO.

“We are very proud of this achievement, and we feel even more challenged to give further leaps ahead. Environmental, social and economic concerns are a part of the company’s values in order to maintain its sustained growth. This is a transversal issue and a part of the organization’s strategic dimensions, which strives to increasingly become a global, innovative and sustainable business”, said Maria del Pilar Muñoz, Eurofarma’s Vice-President of Sustainability and New Business.

In 2008, when it created a Sustainability Board, which later on became a Vice-Presidency office, the company defined its first Sustainability Master Plan. Some of its most recent achievements have been:

Environmental

• A sustainable 78% ethanol-driven fleet with more than 4 thousand flex vehicles
• Reutilization of 77,027 m3 of waste water
• 640 tons of CO2 in avoided emissions
• Disposal of 92% of hazardous waste for co-processing
• 23.5 million product units bearing the +Verde (+Green) seal
• The only company to have achieved 100% post-consumption recycling of used packages
• Entering into agreements on self-production of energy and a 100% clean matrix in Brazil by 2024
• Electric trucks and executive fleet with 155 hybrid vehicles
• Investments amounting to R$ 32.6 million in environmental actions
• Issuance of the 1st sustainable certificate in Brazil

Social

• 50% of women in high-management positions
• For leadership positions, 70% of in-house staff promotions
• More than 11 thousand students supported every year
• More than 130 thousand persons benefited by the Eurofarma Institute since its foundation
• Social investments amounting to R$ 78.6 million
• R$ 18 million in humanitarian aid
• 88% satisfaction level among consumers
• 19 consecutive years among the best companies to work for
• 85% of its collaborators have claimed to be proud of working at Eurofarma
• Donation of +300 thousand medicinal products and +190 thousand basic food baskets

Governance 

• 17% average growth in the last 15 years
• AAA rating according to the Fitch Ratings agency
• Entry into the American market, the largest pharmaceutical market in the world
• +1.700 products
• A 25% EBITDA Margin
• 3 strategic acquisitions this year, one of them in Brazil
• 439 million produced units
• 25 applied patent requests
• Pipeline with +400 projects and investments of +R$ 590 million in R&D
• FDA approval of the Itapevi industrial complex
• Management Board with independent members
• Leadership in medical prescription services in Brazil

Details on all of Eurofarma’s actions are available in its 2023 Sustainability Report (2022 base year). Click here to download it.

About Eurofarma

Founded in 1972, Eurofarma operates in the health sector through the production and commercialization of products and services to improve people’s quality of life. With a focus on the generation of shared value, it covers all the main pharmaceutical segments, such as Medical Prescriptions, Generic Drugs, OTC, Hospital Services, and Oncology. With a broad coverage of therapeutic classes, its portfolio in the region comprises 2.8 thousand SKUs and it services 42 medical specialties.

With operations in 22 countries, especially in Latin America, it is also present in the US and Africa. With more then 11 thousand collaborators, in 2022 it became a public held company as certified by the Brazilian Securities and Exchange Commission (Comissão de Valores Mobiliários - CVM). It reported R$ 8 billion in net revenues, a 13.3% growth if compared to the previous year, with an EBITDA of R$ 2 billion, a 20% evolution. As regards R&D, investments last year added up to more than R$ 590 million, equivalent to 7.4% of its net income.

Eurofarma in social media

Facebook: @eurofarma | LinkedIn: @eurofarma

Instagram: @eurofarma | Youtube: @eurofarmalab

Press Information

G&A – Public Relations

Luciana Lima - 11 98578-1604 – Luciana.lima@gaspar.com.br 

Guilherme Gaspar - 11 98285-6000 - guilherme@gaspar.com.br